Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 100 av 251 resultater
Tid
Selskap
Tittel
Sektor
Kategori
18 Dec 2023
07:00 CET
INNATE PHARMA
Innate Pharma annonce un changement de direction
20103010 Biotechnology
Journal / appointments
18 Dec 2023
07:00 CET
INNATE PHARMA
Innate Pharma Announces Leadership Change
20103010 Biotechnology
Journal / appointments
11 Dec 2023
07:00 CET
INNATE PHARMA
Innate Pharma partage les résultats d’efficacité et de tolérance de la Phase 1/2 avec le NK cell engager SAR443579 / IPH6101 developpé par Sanofi à l’ASH 2023
20103010 Biotechnology
Products and services
11 Dec 2023
07:00 CET
INNATE PHARMA
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
20103010 Biotechnology
Products and services
10 Dec 2023
07:00 CET
INNATE PHARMA
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
20103010 Biotechnology
Products and services
10 Dec 2023
07:00 CET
INNATE PHARMA
Innate Pharma présente les résultats positifs de l’étude de Phase 2 TELLOMAK évaluant lacutamab dans le syndrome de Sézary au congrès annuel de l’ASH 2023
20103010 Biotechnology
Products and services
27 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma to Host Virtual KOL Event on Lacutamab
20103010 Biotechnology
Meetings / events
27 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma organise une conférence virtuelle avec un expert autour de lacutamab
20103010 Biotechnology
Meetings / events
14 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
20103010 Biotechnology
Income
14 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma présente ses résultats financiers au troisième trimestre 2023
20103010 Biotechnology
Income
07 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
20103010 Biotechnology
Meetings / events
07 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma organise une conférence téléphonique pour ses résultats financiers au troisième trimestre 2023
20103010 Biotechnology
Meetings / events
03 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma annonce la présentation de nouvelles données cliniques pour lacutamab et SAR443579/IPH6101 à l’ASH 2023
20103010 Biotechnology
Meetings / events
03 Nov 2023
07:00 CET
INNATE PHARMA
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
20103010 Biotechnology
Meetings / events
27 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
20103010 Biotechnology
Meetings / events
27 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma annonce sa participation à de prochaines conférences investisseurs
20103010 Biotechnology
Meetings / events
19 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma publie son calendrier financier pour 2024
20103010 Biotechnology
Meetings / events
19 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma 2024 Financial Calendar
20103010 Biotechnology
Meetings / events
16 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
20103010 Biotechnology
Products and services
16 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma annonce les abstracts sélectionnés au congrès de l’ESMO 2023
20103010 Biotechnology
Products and services
09 Oct 2023
07:00 CEST
INNATE PHARMA
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 3 octobre 2023
20103010 Biotechnology
Other subject
09 Oct 2023
07:00 CEST
INNATE PHARMA
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
20103010 Biotechnology
Other subject
05 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma annonce une mise à jour sur le programme clinique de lacutamab
20103010 Biotechnology
Products and services
05 Oct 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Provides Update on Lacutamab Clinical Program
20103010 Biotechnology
Products and services
22 Sep 2023
07:00 CEST
INNATE PHARMA
Innate Pharma présente les données d’efficacité intermédiaires de l’essai de Phase 2 TELLOMAK actualisées selon les critères Olsen 2022 au congrès annuel de l'EORTC CLTG 2023
20103010 Biotechnology
Meetings / events
22 Sep 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
20103010 Biotechnology
Meetings / events
14 Sep 2023
07:00 CEST
INNATE PHARMA
Innate Pharma présente ses résultats financiers et l’avancée de son portefeuille au premier semestre 2023
20103010 Biotechnology
Income
14 Sep 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Reports First Half 2023 Financial Results and Business Update
20103010 Biotechnology
Income
29 Aug 2023
07:00 CEST
INNATE PHARMA
Innate Pharma annonce sa participation à de prochaines conférences investisseurs et organise une conférence téléphonique pour ses résultats financiers au premier semestre 2023
20103010 Biotechnology
Meetings / events
29 Aug 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
20103010 Biotechnology
Meetings / events
10 Aug 2023
07:00 CEST
INNATE PHARMA
Prochain rendez-vous investisseurs d'Innate Pharma
20103010 Biotechnology
Meetings / events
10 Aug 2023
07:00 CEST
INNATE PHARMA
Innate Pharma to Participate in Upcoming Investor Conference
20103010 Biotechnology
Meetings / events
11 Jul 2023
07:00 CEST
INNATE PHARMA
Premier patient traité dans l'essai clinique de Phase 1/2 évaluant SAR’514 / IPH6401 dans le myélome multiple en rechute ou réfractaire
20103010 Biotechnology
Products and services
11 Jul 2023
07:00 CEST
INNATE PHARMA
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
20103010 Biotechnology
Products and services
07 Jul 2023
07:00 CEST
INNATE PHARMA
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 1er juillet 2023
20103010 Biotechnology
Share history
07 Jul 2023
07:00 CEST
INNATE PHARMA
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
20103010 Biotechnology
Share history
26 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma : Traitement du premier patient dans l’essai de Phase 2 MATISSE évaluant IPH5201 dans les cancers du poumon au stade précoce
20103010 Biotechnology
Products and services
26 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
20103010 Biotechnology
Products and services
16 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
20103010 Biotechnology
Products and services
16 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma présente une augmentation de l’activité clinique de lacutamab dans des résultats d’efficacité intermédiaires de l’essai de Phase 2 TELLOMAK actualisés selon les critères Olsen
20103010 Biotechnology
Products and services
12 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
20103010 Biotechnology
Meetings / events
12 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma présentera des données d’efficacité mises à jour de l’essai de Phase 2 avec lacutamab dans le mycosis fongoide au congrès de l’ICML
20103010 Biotechnology
Meetings / events
10 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma présente IPH6501, son NK Cell Engager ANKET® tétra-spécifique propriétaire, au congrès 2023 de l’EHA
20103010 Biotechnology
Meetings / events
10 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
20103010 Biotechnology
Meetings / events
08 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma : SAR’579/IPH6101 obtient le statut « Fast Track » de la FDA aux Etats-Unis pour le traitement de maladies hématologiques
20103010 Biotechnology
Products and services
08 Jun 2023
07:00 CEST
INNATE PHARMA
Innate Pharma: SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
20103010 Biotechnology
Products and services
07 Jun 2023
07:00 CEST
INNATE PHARMA
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
20103010 Biotechnology
Share history
07 Jun 2023
07:00 CEST
INNATE PHARMA
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 1er juin 2023
20103010 Biotechnology
Share history
26 May 2023
07:00 CEST
INNATE PHARMA
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
20103010 Biotechnology
Meetings / events
26 May 2023
07:00 CEST
INNATE PHARMA
Innate Pharma annonce les premières données d’escalade de dose et d’efficacité de la Phase 1/2 avec le NK cell engager SAR’579/IPH6101 développé par Sanofi dans la leucémie aiguë myéloïde réfractaire ou récidivante
20103010 Biotechnology
Meetings / events
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva